Investor Relations

BIO International Convention

Jun 3 – Jun 6, 2024

Upcoming Event

BIO International Convention

Latest Financial Results

Q3 2024

Quarter Ended Dec 31, 2023

Latest Annual Filing

For Fiscal Year Ending Mar 31, 2023

Company Overview

Acasti is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Acasti's novel technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Acasti's lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Acasti's lead clinical asset, GTX-104, is an intravenous infusion targeting aneurysmal subarachnoid hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.

The Company’s three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents. The lead assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists; and (iii) GTX-101, a topical spray, targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.

Stock Snapshot

IR Contacts

Headquarters

Acasti Pharma Inc.
103 Carnegie Center
Suite 300
Princeton, NJ 08540
T: 450-687-2262
info@acasti.com

Investor Relations

LifeSci Advisors
Mike Moyer
Managing Director
T: 617-308-4306
mmoyer@lifesciadvisors.com

Transfer Agent

Computershare Trust Company of Canada
650 de Maisonneuve West
7<sup>th</sup> Floor
Montreal, QC H3A 3T2
T: 514-982-7888
https://www.computershare.com/ca/en